Nuwellis decoration

News Release

Nuwellis, Inc. Announces First Quarter 2022 Financial Results

May 10, 2022

MINNEAPOLIS, May 10, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022, which included the following highlights:

  • Generated $1.9 million in total revenue for the first quarter 2022, up 17% sequentially from the fourth quarter of 2021
  • Received a Category III CPT Code effective January 1, 2022, specifically for the use of therapeutic ultrafiltration, thereby increasing reimbursement to professionals and facilities, an important step in advancing Aquadex to standard of care
  • On track to enroll first patients in REVERSE-HF, a randomized controlled multi-center clinical trial designed to validate clinical outcomes and the economic value of Aquadex therapy
  • First quarter 2022 cash flow from operations improved $0.6 million compared to the prior-year period

“I am very pleased with the resilient performance in the quarter,” said Nestor Jaramillo, CEO of Nuwellis. “Going forward, we expect to continue benefiting from the successful execution of our strategy and rollout of our new sales management system.”

First Quarter 2022 Financial Results

Total revenue for the first quarter of 2022 was $1.9 million, an increase of 17% compared to the fourth quarter of 2021 and even with the prior-year period. Growth in the quarter was fueled by higher sales of consumables. Capital equipment sales increased sequentially but were below the prior year, while total monthly year-on-year sales comparisons improved as the business advanced through the quarter.

Gross margin was 57.2% for the first quarter 2022, compared to 50.4% in the prior-year period, with the increase driven primarily by favorable product sales mix and reduced inventory revaluation expense.

Selling, general and administrative expenses for the first quarter of 2022 were $4.4 million, representing a 16% reduction compared to the prior-year period. This reduction resulted from continued cost vigilance and certain non-recurring administrative costs in the prior-year period.   

First-quarter research and development expenses were $1.1 million dollars, compared to $0.9 million dollars in the first quarter of 2021. This increase reflects investment in our dedicated pediatric device.

The net loss for the first quarter of 2022 was $4.5 million, compared to a net loss of $5.2 million in the prior-year period. This resulted in $0.6 million lower net cash used in operating activities.

Cash and cash equivalents were approximately $19.3 million as of March 31, 2022.

Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 6092276. An audio archive of the webcast will be available following the call at

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, MN, with a wholly owned subsidiary in Ireland.

About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)

    Three months ended
March 31,
    2022     2021    
Net sales $ 1,926   $ 1,918  
Cost of goods sold   824     952  
Gross profit   1,102     966  
Operating expenses:            
Selling, general and administrative   4,412     5,237  
Research and development   1,106     947  
Total operating expenses   5,518     6,184  
Loss from operations   (4,416 )   (5,218 )
Other income (expense), net   (55 )   (1 )
Loss before income taxes   (4,471 )   (5,219 )
Income tax expense   (2 )   (2 )
Net loss $ (4,473 ) $ (5,221 )
Basic and diluted loss per share $ (0.42 ) $ (1.62 )
Weighted average shares outstanding – basic and diluted   10,538     3,242  
Other comprehensive loss:            
Unrealized foreign currency translation adjustments $ (2 ) $ (3 )
Total comprehensive loss $ (4,475 ) $ (5,224 )

Consolidated Balance Sheets
(In thousands, except share and per share amounts)

    March 31,
    December 31,
ASSETS   (unaudited)      
Current assets          
Cash and cash equivalents $ 19,300     $ 24,205  
Accounts receivable   951       750  
Inventories   3,294       2,843  
Other current assets   350       328  
Total current assets   23,895       28,126  
Property, plant and equipment, net   1,153       1,188  
Operating lease right-of-use asset   1,038       1,082  
Other assets   21       21  
TOTAL ASSETS $ 26,107     $ 30,417  
Current liabilities          
Accounts payable $ 1,797     $ 1,414  
Accrued compensation   1,335       1,664  
Current portion of operating lease liability   181       167  
Current portion of finance lease liability   24       26  
Other current liabilities   55       36  
Total current liabilities   3,392       3,307  
Operating lease liability   909       956  
Finance lease liability   22       28  
Other long-term liability   71       179  
Total liabilities   4,394       4,470  
Commitments and contingencies          
Stockholders’ equity          
Series A junior participating preferred stock as of March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 30,000 shares, none outstanding          
Series F convertible preferred stock as of both March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares          
Preferred stock as of both March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding          
Common stock as of March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 10,537,606 shares   1       1  
Additional paid-in capital   279,114       278,873  
Accumulated other comprehensive income:          
Foreign currency translation adjustment   (13 )     (11 )
Accumulated deficit   (257,389 )     (252,916 )
Total stockholders’ equity   21,713       25,947  

Condensed Consolidated Statements of Cash Flows
(in thousands)

    Three months ended 
March 31,

Operating Activities:            
Net loss $ (4,473 ) $ (5,221 )
Adjustments to reconcile net loss to cash flows used in operating activities:            
Depreciation and amortization   105     126  
Stock-based compensation expense, net   241     355  
Changes in operating assets and liabilities:            
Accounts receivable   (201 )   (14 )
Inventory   (451 )   (89 )
Other current assets   (22 )   (132 )
Other assets and liabilities   (80 )   24  
Accounts payable and accrued expenses   54     (431 )
Net cash used in operating activities   (4,827 )   (5,382 )
Investing Activities:            
Purchases of property and equipment   (70 )   (56 )
Net cash used in investing activities   (70 )   (56 )
Financing Activities:            
Proceeds from public stock offerings, net       18,902  
Proceeds from warrant exercises       1  
Payments on finance lease liability   (6 )   (6 )
Net cash provided (used in) by financing activities   (6 )   18,897  
Effect of exchange rate changes on cash   (2 )   (3 )
Net increase in cash and cash equivalents   (4,905 )   13,456  
Cash and cash equivalents - beginning of period   24,205     14,437  
Cash and cash equivalents - end of period $ 19,300   $ 27,893  
Supplemental cash flow information            
Inventory transferred to property, plant and equipment $   $ 89  


George Montague, CFA
Chief Financial Officer, Nuwellis, Inc.

Matt Bacso, CFA
Gilmartin Group        

Primary Logo

Source: Nuwellis, Inc.